MADRIGAL PHARMACEUTICALS INC
MDGLNASDAQ🏆 #795 by market capEarnings Oct 29 · PreUS Equity
$509.44▼ $7.49 (−1.47%)
🌙 After hours$509.00▼ 0.09%Regular close · extended-hours price shownTrack MDGL
Get earnings, price moves & breaking news on Telegram
24h▼ 1.5%
7d▼ 1.8%
14d▼ 2.6%
30d▼ 4.6%
ytd▼ 12.5%
1y▲ 14.9%
🏦Market Cap
$11.77B
Mid Cap
📈Revenue Growth (YoY)
+432.1%
High Growth
📊Gross Margin
91.5%
High
💵FCF Margin
-16.1%
Thin
⚖️P/S Ratio
9.3x
Elevated
Otter Score
44
Weak
MADRIGAL PHARMACEUTICALS INC
MDGLAnalyst Ratings
Price
$509.44
Total
25
Raised
3
Lowered
1
Avg PT
$680.38
H / L
$962 / $542
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Wolfe Research | Upgraded | Peer Perform → Outperform | 2026-08-04 | $605.00 | +18.80% |
Barclays | Reiterated | Overweight | 2026-08-03 | $962.00 | +88.80% |
Canaccord Genuity | Reiterated | Buy | 2026-07-29 | $587.00 | +15.20% |
B of A Securities | Reiterated | Neutral | 2026-06-11 | — | — |
Truist Securities | Reiterated | Buy | 2026-05-13 | — | — |
Evercore ISI Group | Reiterated | Outperform | 2026-05-07 | — | — |
HC Wainwright & Co. | Reiterated | Buy | 2026-05-06 | — | — |
Citizens | Reiterated | Market Outperform | 2026-01-20 | — | — |
Piper Sandler | Reiterated | Overweight | 2025-12-19 | $900.00 | +76.70% |
B. Riley Securities | Reiterated | Buy | 2025-12-11 | — | — |
Oppenheimer | Reiterated | Outperform | 2025-11-20 | $650.00 | +27.60% |
Cantor Fitzgerald | Upgraded | Neutral → Overweight | 2025-11-05 | — | — |
TD Cowen | Reiterated | Buy | 2025-08-26 | — | — |
JMP Securities | Reiterated | Market Outperform | 2025-08-20 | $527.00 | +3.40% |
UBS | Reiterated | Buy | 2025-08-12 | $900.00 | +76.70% |
Citigroup | Reiterated | Buy | 2025-02-27 | — | — |
Goldman Sachs | Reiterated | Buy | 2022-12-20 | $704.00 | +38.20% |
SVB Leerink | Reiterated | Outperform | 2022-12-20 | — | — |
Chardan Capital | Reiterated | Buy | 2021-02-26 | — | — |
BMO Capital | Reiterated | Market Perform | 2020-11-06 | $111.00 | −78.20% |
B. Riley FBR | Reiterated | Buy | 2020-05-22 | — | — |
Citi | Reiterated | Buy | 2019-12-02 | — | — |
B. Riley | Upgraded | Neutral → Buy | 2019-06-10 | — | — |
Raymond James | Downgraded | Market Perform → Underperform | 2018-11-19 | — | — |
H.C. Wainwright | Reiterated | Buy | 2018-06-01 | $620.00 | +21.70% |
Institution
Wolfe Research
Upgraded · Peer Perform → Outperform · 2026-08-04
$605.00
+18.80%
Barclays
Reiterated · Overweight · 2026-08-03
$962.00
+88.80%
Canaccord Genuity
Reiterated · Buy · 2026-07-29
$587.00
+15.20%
B of A Securities
Reiterated · Neutral · 2026-06-11
—
—
Truist Securities
Reiterated · Buy · 2026-05-13
—
—
Evercore ISI Group
Reiterated · Outperform · 2026-05-07
—
—
HC Wainwright & Co.
Reiterated · Buy · 2026-05-06
—
—
Citizens
Reiterated · Market Outperform · 2026-01-20
—
—
Piper Sandler
Reiterated · Overweight · 2025-12-19
$900.00
+76.70%
B. Riley Securities
Reiterated · Buy · 2025-12-11
—
—
Oppenheimer
Reiterated · Outperform · 2025-11-20
$650.00
+27.60%
Cantor Fitzgerald
Upgraded · Neutral → Overweight · 2025-11-05
—
—
TD Cowen
Reiterated · Buy · 2025-08-26
—
—
JMP Securities
Reiterated · Market Outperform · 2025-08-20
$527.00
+3.40%
UBS
Reiterated · Buy · 2025-08-12
$900.00
+76.70%
Citigroup
Reiterated · Buy · 2025-02-27
—
—
Goldman Sachs
Reiterated · Buy · 2022-12-20
$704.00
+38.20%
SVB Leerink
Reiterated · Outperform · 2022-12-20
—
—
Chardan Capital
Reiterated · Buy · 2021-02-26
—
—
BMO Capital
Reiterated · Market Perform · 2020-11-06
$111.00
−78.20%
B. Riley FBR
Reiterated · Buy · 2020-05-22
—
—
Citi
Reiterated · Buy · 2019-12-02
—
—
B. Riley
Upgraded · Neutral → Buy · 2019-06-10
—
—
Raymond James
Downgraded · Market Perform → Underperform · 2018-11-19
—
—
H.C. Wainwright
Reiterated · Buy · 2018-06-01
$620.00
+21.70%
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space